Regulatory approval
Published by the Health Products Regulatory Authority.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.
This is written in the approval document as:
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.
Citation
Novartis Ireland Limited. Femara 2.5 mg film-coated tablets (Letrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf. Revised August 2024. Accessed May 25, 2025.Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Letrozole | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Letrozole | |
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Letrozole |